ALNY

Alnylam Pharmaceuticals, Inc. Press Releases

$67.04
*  
0.84
1.24%
Get ALNY Alerts
*Delayed - data as of Apr. 29, 2016  -  Find a broker to begin trading ALNY now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    ALNY After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing

Alnylam to Break Ground on New Manufacturing Facility in Norton, Massachusetts
4/28/2016 7:00:00 AM - Business Wire
▼-2.32 % Price Change since this news event. The Volume Ratio is 0.95.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Alnylam to Webcast Presentations at Upcoming May Investor Conferences
4/26/2016 4:00:00 PM - Business Wire
▼-4.73 % Price Change since this news event. The Volume Ratio is 0.83.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Alnylam to Webcast Conference Call Discussing First Quarter 2016 Financial Results
4/25/2016 4:00:00 PM - Business Wire
▼-6.82 % Price Change since this news event. The Volume Ratio is 0.98.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Alnylam Reports Complete 18-Month Data from Ongoing Phase 2 Open-Label Extension Study of Patisiran, an Investigational RNAi Therapeutic Targeting Transthyretin for the Treatment of Hereditary ATTR Amyloidosis with Polyneuropathy (hATTR-PN)
4/20/2016 7:00:00 AM - Business Wire
▲0.19 % Price Change since this news event. The Volume Ratio is 0.95.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Alnylam to Webcast Presentation at 15th Annual Needham Healthcare Conference
4/6/2016 4:00:00 PM - Business Wire
▼-8.16 % Price Change since this news event. The Volume Ratio is 1.88.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Alnylam Initiates Fitusiran (ALN-AT3) Dosing in Hemophilia A and B Patients with Inhibitors in Ongoing Phase 1 Study
3/14/2016 8:00:00 AM - Business Wire
▲7.87 % Price Change since this news event. The Volume Ratio is 1.37.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Alnylam Initiates Phase 1/2 Clinical Trial for ALN-GO1, an Investigational RNAi Therapeutic for the Treatment of Primary Hyperoxaluria Type 1 (PH1)
3/9/2016 8:00:00 AM - Business Wire
▲16.53 % Price Change since this news event. The Volume Ratio is 1.76.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




Alnylam to Webcast Presentations at Upcoming March Investor Conferences
2/29/2016 8:00:00 AM - Business Wire
▲15.59 % Price Change since this news event. The Volume Ratio is 1.77.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results and Highlights Recent Period Progress
2/11/2016 4:00:00 PM - Business Wire
▲17.70 % Price Change since this news event. The Volume Ratio is 1.52.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2015 Financial Results
2/4/2016 4:00:00 PM - Business Wire
▼-0.70 % Price Change since this news event. The Volume Ratio is 1.07.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Alnylam to Webcast Presentations at Upcoming February Investor Conferences
2/1/2016 4:00:00 PM - Business Wire
▼-3.89 % Price Change since this news event. The Volume Ratio is 1.1.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Alnylam Completes Enrollment in APOLLO Phase 3 Study with Patisiran, an Investigational RNAi Therapeutic for Patients with Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)
2/1/2016 8:00:00 AM - Business Wire
▼-2.76 % Price Change since this news event. The Volume Ratio is 1.49.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day